Pila Pharma investor relations material

PILA PHARMA AB (publ) is a clinical stage pharmaceutical company developing XEN-D0501, a TRPV1 antagonist targeting the prevention and treatment of type 2 diabetes. The product candidate has completed two phase 2a clinical trials. Once it completes its ongoing phase 2b trial, PILA PHARMA AB (publ) is planning to initiate pivotal phase 3 study.